Insider Transactions in Q2 2021 at Heron Therapeutics, Inc. (HRTX)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 21
2021
|
Craig A Johnson Director |
SELL
Open market or private sale
|
Direct |
250
-6.96%
|
$3,750
$15.2 P/Share
|
|
Jun 21
2021
|
Waage Christian Director |
SELL
Open market or private sale
|
Direct |
300
-7.32%
|
$4,500
$15.2 P/Share
|
|
May 03
2021
|
Kimberly Manhard EVP, Drug Development |
SELL
Open market or private sale
|
Direct |
1,529
-48.34%
|
$25,993
$17.66 P/Share
|
|
Apr 30
2021
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Other acquisition or disposition
|
Direct |
1,530
+10.2%
|
$19,890
$13.9 P/Share
|
|
Apr 30
2021
|
John Poyhonen President & CCO |
BUY
Other acquisition or disposition
|
Direct |
971
+4.34%
|
$12,623
$13.9 P/Share
|
|
Apr 30
2021
|
Barry D Quart Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
1,529
+1.56%
|
$19,877
$13.9 P/Share
|
|
Apr 30
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Other acquisition or disposition
|
Direct |
1,530
+39.46%
|
$19,890
$13.9 P/Share
|
|
Apr 30
2021
|
Kimberly Manhard EVP, Drug Development |
BUY
Other acquisition or disposition
|
Direct |
1,529
+32.59%
|
$19,877
$13.9 P/Share
|
|
Apr 15
2021
|
Waage Christian Director |
SELL
Open market or private sale
|
Direct |
300
-6.82%
|
$5,100
$17.51 P/Share
|
|
Apr 13
2021
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-20.95%
|
$6,928
$16.66 P/Share
|
|
Apr 13
2021
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+37.68%
|
-
|
|
Apr 13
2021
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
191
-1.57%
|
$3,056
$16.66 P/Share
|
|
Apr 13
2021
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
552
+4.35%
|
-
|
|
Apr 13
2021
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-2.08%
|
$6,928
$16.66 P/Share
|
|
Apr 13
2021
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+5.66%
|
-
|
|
Apr 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
433
-34.64%
|
$6,928
$16.66 P/Share
|
|
Apr 13
2021
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+50.0%
|
-
|
|
Apr 13
2021
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
963
-1.0%
|
$15,408
$16.66 P/Share
|
|
Apr 13
2021
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,646
+3.65%
|
-
|
|
Apr 06
2021
|
Craig A Johnson Director |
SELL
Open market or private sale
|
Direct |
250
-6.51%
|
$4,250
$17.22 P/Share
|